Impact of Microparticle Transarterial Chemoembolization (mTACE) on myeloid‐derived suppressor cell subtypes in hepatocellular carcinoma: Clinical correlations and therapeutic implications
Yuanxun Yue,Zhizhong Ren,Yaqin Wang,Ying Liu,Xiaowei Yang,Tianxiao Wang,Yating Bai,He Zhou,Qian Chen,Sujun Li,Yuewei Zhang
DOI: https://doi.org/10.1002/iid3.70007
2024-09-04
Immunity Inflammation and Disease
Abstract:The research highlights the therapeutic potential of targeting monocytic myeloid‐derived suppressor cells (mMDSCs) and demonstrates the effectiveness of Microparticle TACE (mTACE) in reshaping the immunosuppressive tumor microenvironment. This offers new avenues for innovative immunotherapeutic approaches in hepatocellular carcinoma (HCC) management. It investigates the clinical correlations between MDSC frequencies, specifically mMDSCs, and aggressive HCC features like tumor size, vascular invasion, and distant metastasis. The study delves into the immunological consequences of mTACE, a treatment gaining prominence for inducing significant tumor necrosis in unresectable HCC. Background Myeloid‐derived suppressor cells (MDSCs) play a pivotal role in immunosuppression and tumor progression in hepatocellular carcinoma (HCC). While various treatments like surgical resection, ablation, and radiotherapy have been studied for their effects on circulating MDSC frequencies in HCC patients, the findings remain inconclusive. Transarterial Chemoembolization (TACE) stands as the standard care for unresectable HCC, with Microparticle TACE (mTACE) gaining prominence for its capacity to induce significant tumor necrosis. However, the immunological ramifications of such pathological outcomes are scarcely reported. Methods and Results This study aims to elucidate the alterations in MDSC subtypes, specifically monocytic MDSCs (mMDSCs) and early‐stage MDSCs (eMDSCs), post‐mTACE and to investigate their clinical correlations in HCC patients. A cohort comprising 75 HCC patients, 16 liver cirrhosis patients, and 20 healthy controls (HC) was studied. Peripheral blood samples were collected and analyzed for MDSC subtypes. The study also explored the associations between MDSC frequencies and various clinical parameters in HCC patients. The frequency of mMDSCs was significantly elevated in the HCC group compared to liver cirrhosis and HC. Importantly, mMDSC levels were strongly correlated with aggressive clinical features of HCC, including tumor size, vascular invasion, and distant metastasis. Post‐mTACE, a marked reduction in mMDSC frequencies was observed, while eMDSC levels remained stable. Conclusions Our findings underscore the critical role of mMDSCs in HCC pathogenesis and their potential as a therapeutic target. The study also highlights the efficacy of mTACE in modulating the immunosuppressive tumor microenvironment, thereby opening new avenues for combinatorial immunotherapeutic strategies in HCC management.
immunology